Seeking Alpha

Sangamo BioSciences affirms full-year revenue, operating expense guidance

  • Sangamo BioSciences (SGMO) puts up a largely in line quarter (revenues come largely from collabs with Shire and Sigma-Aldrich).
  • R&D expense for the period was $8.7M, up from $7.6M in Q3 2012.
  • Full year guidance: Revenues of $20-24M and operating expenses of $46-50M. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: